Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03806127 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome
A Phase 2 study, sponsored by Urovant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT03806127 is a Phase 2 study that has completed, run by Urovant Sciences. The registered enrollment target is 222 participants.
The verdict
NCT03806127, a Phase 2 study, has completed, sponsored by Urovant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M).
Interventions
- DRUG Placebo
- DRUG Vibegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2018-12-31 |
| Est. Completion | 2020-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03806127
The ClinicalTrials.gov registry entry for NCT03806127 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Urovant Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03806127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03806127 about?
NCT03806127 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome". This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (β3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M).
What is the current status of trial NCT03806127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2018-12-31. Estimated completion is 2020-10-06.
What interventions are being tested in trial NCT03806127?
The interventions under investigation include: Placebo (DRUG), Vibegron (DRUG).
Who is sponsoring clinical trial NCT03806127?
This trial is sponsored by Urovant Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.